Skin & Hair Peptide Dosage Protocols
Skin and hair research peptides include melanocortin receptor agonists (Melanotan I/II) and copper-binding tripeptides (GHK-Cu) used for collagen synthesis and ECM remodeling studies.
5 protocols indexed
SNAP-8
SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide derivative of Argireline developed as a topical cosmetic ingredient for reducing the appearance of expression lines and dynamic wrinkles. It mimics the N-terminal sequence of SNAP-25, a key SNARE protein involved in acetylcholine release at the neuromuscular junction. By interfering with vesicle docking at presynaptic terminals of facial mimetic muscles, SNAP-8 produces a localized, transient reduction in muscle contraction intensity without systemic absorption. SNAP-8 is used exclusively as a topical cosmetic agent at concentrations of 5–10% in serums, creams, and eye contour products. It is not approved for injection and has no documented systemic pharmacology in humans. Manufacturer-sponsored studies report wrinkle depth reductions of approximately 30–35% after 28 days of twice-daily topical application. SNAP-8 is generally regarded as safe for topical use, with very low rates of irritation or allergic contact dermatitis, and is widely incorporated into anti-aging cosmetic formulations as a non-invasive alternative to botulinum toxin.
Open Protocolarrow_forwardResearch PeptideGHK-Cu
GHK-Cu is the copper-binding tripeptide glycyl-L-histidyl-L-lysine complexed with divalent copper, first isolated from human plasma by Loren Pickart in 1973. Plasma concentrations decline with age, and the molecule has become one of the most extensively studied bioactive peptides in dermatology and regenerative medicine. GHK-Cu modulates over four thousand human genes at nanomolar concentrations, shifting expression patterns associated with damaged or aged tissue toward profiles characteristic of younger, healthier tissue. It accelerates wound healing, stimulates collagen, elastin, and proteoglycan synthesis, modulates matrix metalloproteinase activity, promotes angiogenesis, and supports hair follicle regeneration. In dermatology and cosmetics, GHK-Cu is used topically at concentrations of 0.05% to 2% in serums, creams, and scalp formulations. Injectable and intranasal protocols are explored in research settings only. Tolerability is excellent for topical use; the most common adverse events are mild irritation or temporary blue-green staining of skin or fabrics from the copper complex itself.
Open Protocolarrow_forwardMelanocortin / Tanning & LibidoMelanotan II
Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona by Hadley, Hruby, Dorr and colleagues in the 1980s as a stable, broadly active melanocortin receptor agonist. It activates MC1R, MC3R, MC4R, and MC5R, producing eumelanin pigmentation in skin and hair (MC1R), centrally mediated penile erection and sexual desire (MC3R/MC4R), appetite suppression and increased energy expenditure (MC4R), and exocrine effects (MC5R). Research subcutaneous dosing typically begins at 0.10–0.25 mg and titrates up to 0.5–1 mg per administration after gradual desensitization to nausea. Melanotan II is not approved by any major regulator for human use. Documented risks include nausea and flushing, spontaneous erections, blood pressure changes, eruptive and darkening melanocytic nevi, and isolated case reports of melanoma emerging in users. Long-term safety has not been established, and the peptide is not recommended for routine cosmetic tanning.
Open Protocolarrow_forwardTherapeutic BlendGLOW
GLOW is a research peptide blend that combines three regenerative compounds in a single vial: BPC-157 (pentadecapeptide derived from gastric juice protein BPRP), TB-500 (synthetic Thymosin Beta-4 fragment), and GHK-Cu (copper-tripeptide glycyl-L-histidyl-L-lysine). Typical research formulations contain ten milligrams of BPC-157, ten milligrams of TB-500, and fifty milligrams of GHK-Cu per vial. The blend is administered subcutaneously, often at doses delivering 250–500 micrograms of BPC-157, 250–500 micrograms of TB-500, and 1–2 mg of GHK-Cu per injection two to five times weekly. GLOW is marketed for skin rejuvenation, hair quality, post-procedure recovery, soft tissue repair, and inflammation modulation. None of the components are FDA approved, and the blend has never been studied as a fixed combination in published clinical trials. Evidence rests entirely on animal data and mechanistic studies of the individual peptides.
Open Protocolarrow_forwardSynergistic StackPT-141 + Melanotan II
PT-141 (bremelanotide) and Melanotan II are structurally related melanocortin receptor agonists derived from the same University of Arizona research program. Melanotan II is a non-selective MC1R/MC3R/MC4R/MC5R agonist used in research for tanning and sexual function. PT-141 is a metabolite of Melanotan II with greater selectivity for MC3R and MC4R and minimal MC1R-driven pigmentation; the FDA approved it in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Some users combine the two peptides to achieve cosmetic tanning (MT-II) plus enhanced sexual response (PT-141). Combined dosing has not been formally studied. Research subcutaneous protocols typically use 0.25–1 mg MT-II during a loading phase plus 0.5–1.75 mg PT-141 as needed before sexual activity. The stack amplifies common melanocortin side effects (nausea, flushing, blood pressure changes) and adds the long-term dermatologic and oncologic risks associated with MT-II, including new and darkening nevi.
Open Protocolarrow_forward